Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC

This is a Phase II clinical trial evaluating the efficacy and safety of a new treatment approach for patients with locally advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes on the opposite side of the chest (known as N3 lymph node involvement). The study will enroll 28 patients aged 18 to 75 years with previously untreated, potentially resectable NSCLC classified as stage IIIB-IIIC. Participants will receive a combination of stereotactic body radiation therapy (SBRT) to the primary lung tumor, followed by two cycles of sintilimab (an immunotherapy drug) plus platinum-

Trial Details

NCT ID
NCT07309952
Phase
PHASE2
Sponsor
Yang Hong
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Sintilimab
  • Paclitaxel
  • Carboplatin (AUC 5)
  • Pemetrexed 500 mg/m2
  • Stereotactic body radiotherapy (SBRT)
  • non-small cell lung cancer
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Voluntary Participation: The patient volunteers to participate and signs a written informed consent form.
  • Pathology and Staging: Cytologically or histologically confirmed, previously untreated non-small cell lung cancer (NSCLC) with contralateral medias…
  • Surgical Feasibility: The lung lesion is considered \*\*potentially resectable as evaluated by a multidisciplinary team that includes a thoracic su…
  • Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →